There are 2789 resources available
720TiP - Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
Presenter: Rohit Jain
Session: ePoster Display
643TiP - Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors
Presenter: Hendrik-Tobias Arkenau
Session: ePoster Display
646TiP - A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: The PEACE 2 trial from Unicancer
Presenter: Pierre Blanchard
Session: ePoster Display
648TiP - PSMAfore: A phase III study to compare <sup>177</sup>Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC
Presenter: Michael Morris
Session: ePoster Display
649TiP - PRIMORDIUM: A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancer
Presenter: Boris Hadaschik
Session: ePoster Display
650TiP - PARADIGM: Plasma analysis for response assessment and to direct the management of metastatic prostate cancer (mPCa)
Presenter: Anuradha Jayaram
Session: ePoster Display
660P - Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
Presenter: Toni Choueiri
Session: ePoster Display